DNA甲基化来源的系统性炎症指标与口咽癌风险及生存的关联
纳入94例口咽鳞状细胞癌(OPSCC)病例和57例对照,分析DNA甲基化来源的系统性炎症(mdSI)指标与OPSCC风险及生存的关联。较高的甲基化来源中性粒细胞与淋巴细胞比值(mdNLR)与OPSCC风险增加相关(OR=1.21,95%CI:1.11-1.40);较高的mdLMR与5年总生存死亡风险降低显著相关(HR=0.25,95%CI:0.10-0.64),mdNLR则相反(HR=2.48,95%CI:1.04-5.92)。作者认为mdLMR可能作为OPSCC的独立预后因素。
要点
- 较高的mdNLR与OPSCC风险增加相关(OR=1.21,95%CI:1.11-1.40)。
- 较高的mdLMR与5年总生存死亡风险降低显著相关(HR=0.25,95%CI:0.10-0.64)。
- 较高的mdNLR与5年总生存死亡风险升高相关(HR=2.48,95%CI:1.04-5.92)。
核心结论
- mdSI指标与OPSCC风险及5年总生存存在关联。
- 作者认为mdLMR可能作为OPSCC的独立预后因素。
研究设计与样本
- 纳入94例口咽鳞状细胞癌(OPSCC)病例和57例对照,均有DNA甲基化数据。
- 采用逻辑回归分析检验mdSI指标与OPSCC风险的关联,并进行了生存分析。
主要发现
- 较高的甲基化来源中性粒细胞与淋巴细胞比值(mdNLR)与OPSCC风险增加相关(OR=1.21,95%CI:1.11-1.40)。
- 甲基化来源淋巴细胞与单核细胞比值(mdLMR)与OPSCC风险无关联。
- 对于5年总生存,较高的mdLMR与死亡风险降低显著相关(HR=0.25,95%CI:0.10-0.64)。
- 对于5年总生存,较高的mdNLR与死亡风险升高相关(HR=2.48,95%CI:1.04-5.92)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinomas are associated with systemic inflammation (SI). We evaluated whether DNA methylation-derived SI (mdSI) indices are associated with oropharyngeal cancer risk and survival. METHODS: Ninety-four oropharyngeal squamous cell carcinoma (OPSCC) cases and 57 controls with DNA methylation data were included. Logistic regression analysis and survival analysis were performed to test the association of mdSI indices with OPSCC risk and survival. RESULTS: Higher methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) was associated with increased risk of OPSCC (OR = 1.21, 95%CI: 1.11-1.40) while no association was found with methylation-derived lymphocyte-to-monocyte ratio (mdLMR). For 5-year overall survival, higher mdLMR was significantly associated with decreased risk of death (HR = 0.25, 95%CI: 0.10-0.64) while the converse was observed for mdNLR (HR = 2.48, 95%CI: 1.04-5.92). CONCLUSION: We observed an association between mdSI indices and OPSCC risk and 5-year overall survival. It is possible to use mdLMR as an independent prognostic factor for OPSCC.
引用
- Yang B, Eliot M, McClean MD, et al. DNA methylation-derived systemic inflammation indices and their association with oropharyngeal cancer risk and survival. Head Neck. 2022. PMID: 35048488. doi:10.1002/hed.26981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。